15 Biggest Mid-Day Gainers For Monday

Loading...
Loading...
  • TG Therapeutics Inc TGTX shares surged 88.8 percent to $10.10 after the company disclosed that Phase 3 GENUINE study met its primary endpoint.
  • Concert Pharmaceuticals Inc CNCE shares climbed 79.5 percent to $17.32. Vertex Pharmaceuticals Incorporated VRTX announced plans to acquire CTP-656 from Concert Pharma for $160 million in cash and potential $90 million in milestones.
  • Dextera Surgical Inc DXTR shares jumped 36.8 percent to $1.56 after the company disclosed that MicroCutter 5/80 surgical stapler enabled shorter hospital stays through less invasive lobectomy.
  • ChinaCache International Holdings Ltd CCIH shares climbed 23 percent to $2.46 as the company agreed to sell data center assets for total consideration of RMB$221.2 million.
  • Skypeople Fruit Juice Inc SPU shares rose 18 percent to $5.93 as the company disclosed that it has entered into one-year business agreement with China Aigo O2O Technology Inc.
  • Quest Resource Holding Corp QRHC gained 14.7 percent to $2.51. Rodman & Renshaw initiated coverage on Quest Resource with a Buy rating.
  • Novan Inc NOVN surged 14.1 percent to $7.29. Novan announced plans to continue SB204 development program.
  • NXT-ID Inc NXTD shares rose 13.1 percent to $2.07.
  • Polar Power Inc POLA shares gained 12.5 percent to $9.88 after the company reported 2016 financial results.
  • Ever-Glory International Group Inc EVK shares surged 12 percent to $2.80.
  • Bellerophon Therapeutics Inc BLPH shares gained 9 percent to $1.53.
  • Advaxis, Inc. ADXS rose 7.4 percent to $9.90 after the company reported the FDA acceptance of IND for ADXS-NEO. The company announced plans to initiate Phase 1 trial in 2017.
  • Aurinia Pharmaceuticals Inc AUPH shares rose 7.1 percent to $5.15 after gaining 6.18 percent on Friday.
  • Minerva Neurosciences Inc NERV shares surged 5.4 percent to $8.75. Jefferies initiated coverage on Minerva Neurosciences with a Buy rating.
  • PTC Therapeutics, Inc. PTCT shares gained 4 percent to $10.20. PTC Therapeutics reported FDA acknowledgment of NDA filing for Translarna.
Loading...
Loading...
date
▲▼
ticker
▲▼
name
▲▼
Price Target
▲▼
Upside/Downside
▲▼
Recommendation
▲▼
Firm
▲▼
Posted In: NewsIntraday UpdateAnalyst RatingsMoversHealth CarePharmaceuticalsTop Gainers
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...